Teva Pharmaceutical Industries (TEVA) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viatris (VTRS) has outperformed Teva Pharmaceutical Industries (TEVA) over the past year, gaining 87.7% versus a gain of 62.0%. Over five years, TEVA leads with a +362.1% price change compared with +54.0% for VTRS. Teva Pharmaceutical Industries is the larger company by market cap ($45.77 billion vs $22.50 billion), about 2.0 times the size.
On valuation, Viatris trades at a lower forward P/E (6.9x vs 12.5x for Teva Pharmaceutical Industries). Viatris pays a dividend yielding 2.45%, while Teva Pharmaceutical Industries does not currently pay one. Teva Pharmaceutical Industries converts more of its revenue into profit, with a net margin of 8.2% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TEVA | VTRS |
|---|---|---|
| Share price | $39.23 | $19.63 |
| Market cap | $45.77B | $22.50B |
| 1-day change | +1.79% | -1.26% |
| YTD return | +25.70% | +57.67% |
| 1-year return | +62.04% | +87.67% |
| 5-year return | +362.07% | +53.96% |
| P/E ratio (TTM) | 91.23 | — |
| Forward P/E | 12.53 | 6.94 |
| EPS (TTM) | $0.43 | $-0.53 |
| Dividend yield | 0.00% | 2.45% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $17.26B | $14.30B |
| Revenue growth (YoY) | +4.32% | -2.98% |
| Net income (latest FY) | $1.41B | $-3.51B |
| Gross margin | 51.79% | 35.06% |
| Operating margin | 12.50% | -18.62% |
| Net margin | 8.17% | -24.58% |
| 52-week high | $44.57 | $21.20 |
| 52-week low | $24.34 | $10.39 |
| Distance from 52-week high | -11.98% | -7.41% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +28.19% | +10.04% |
| Average volume | 6.31M | 9.11M |
| Shares outstanding | 1.17B | 1.15B |
| Employees | 31,173 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 2.0 times larger than Viatris by market value ($45.77B vs $22.50B).
- VTRS has outperformed TEVA by 25.6 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.45% vs 0.00%).
- Teva Pharmaceutical Industries is more profitable, keeping 8.2 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Teva Pharmaceutical Industries grew revenue faster in its latest fiscal year (+4.32% vs -2.98%).
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
TEVA vs VTRS FAQ
Which is bigger, Teva Pharmaceutical Industries or Viatris?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.77B compared with $22.50B for Viatris (VTRS).
Which stock has performed better over the past year, TEVA or VTRS?
VTRS returned +87.67% over the past 12 months, compared with +62.04% for TEVA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Teva Pharmaceutical Industries or Viatris?
Viatris pays a dividend yielding 2.45%, while Teva Pharmaceutical Industries does not currently pay a regular dividend.
Are Teva Pharmaceutical Industries and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.